News J&J diabetes drug hit by amputation risk Invokana produces modest CV benefit, but doubles risk of amputation
News Pfizer drug gets fast review in rare heart condition FDA grants faster and development and review process.
Views & Analysis ADA preview: cardio data in diabetes, drug costs and healthc... Invokana data could suggest cardio benefit for SGLT2 class.
News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News AZ’s Bydureon disappoints in diabetes outcomes trial Results give advantage to Boehringer/Lilly's Jardiance.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
